Lupus & antiphospholipid syndrome
Is antimalarial use associated with a reduced risk of LN in patients with SLE? Results from an inception cohort-based study
Authors' conclusion
Antimalarial use is not significantly associated with a reduced risk of incident LN in SLE patients.
Study context
- Population
- SLE patients from an inception cohort with no prior history of LN; median baseline age 33.6 years (IQR: 24.9–45.4)
- Participants
- 674 patients
- Exposure
- Cumulative duration of antimalarial exposure and risk of incident LN
- Outcome
- Development of LN (new-onset proteinuria attributed to lupus activity by clinical judgement, recorded in the SLEDAI-2K sheet)
Methodological detailstime-dependent univariable Cox proportional hazards model, adjusted multivariable Cox regression
- Time-dependent univariable Cox proportional hazards model
- Adjusted multivariable Cox regression
Main finding
As reported in the abstract
Incident LN (new-onset proteinuria attributed to lupus activity)
Cumulative duration of antimalarial exposureHazard ratio (95% CI)P value
Unadjusted univariable model (overall effect)
0.98(0.94–1.02)
P = 0.25Adjusted multivariable model
0.96(0.92–1.00)
P = 0.08Observational data: associations, not effects.
Further findings
Incident LN, sensitivity analysis in serologically active SLE (subgroup)
| HR (95% CI) | ||
|---|---|---|
| Cumulative duration of antimalarial exposureSensitivity analysis | 0.97 (0.92–1.02) | |
| 0.512Hazard ratio (log scale) |
Original publication
Is antimalarial use associated with a reduced risk of LN in patients with SLE? Results from an inception cohort-based study. Rheumatology (Oxford). Published 11 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →